Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Xofluza Granules 2% – a new formulation for influenza treatment and prophylaxis launched – Shionogi

Written by | 23 Nov 2025

Shionogi & Co., Ltd.  announced the launch  of a new formulation of the anti-influenza virus drug Xofluza (baloxavir marboxil) – Xofluza Granules 2%. Until now, Xofluza has only… read more.

CHMP positive recommendation for Xofluza (baloxavir marboxil) for infant patients in the EU for the treatment of uncomplicated influenza – Roche

Written by | 5 Aug 2025

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Xofluza. The marketing authorisation… read more.

Positive phase III results show Xofluza (baloxavir marboxil) significantly reduces the transmission of influenza viruses – Genentech/Roche

Written by | 24 Sep 2024

Genentech, a member of the Roche Group , announced t positive topline results of the Phase III CENTERSTONE study of Xofluza (baloxavir marboxil), an antiviral, showing a reduction in… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.